Structure And Assembly Of The Hepatitis B Nucleocapsid Protein
乙型肝炎核衣壳蛋白的结构和组装
基本信息
- 批准号:7964902
- 负责人:
- 金额:$ 71.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AddressAffinityAntibodiesAntigen-Antibody ComplexAntigensB-LymphocytesBindingBiotechnologyC-terminalCancer EtiologyCapsidCapsid ProteinsChildhoodChronic Hepatitis BClinicalCodeCollaborationsComplexCryoelectron MicroscopyCytoplasmDetectionDevelopmentDiagnosticDrug Delivery SystemsElasticityEncapsulatedEpitopesFab ImmunoglobulinsGenesHepatitis BHepatitis B Core AntigenHepatitis B VirusHepatitis B e AntigensHeterogeneityHumanImage AnalysisInterventionKineticsKnowledgeLabelLibrariesLife Cycle StagesMapsMass Spectrum AnalysisMeasurementMeasuresMetabolicMethodsModelingMolecularMolecular StructureMonoclonal AntibodiesMusN-terminalNanotechnologyNucleic AcidsNucleocapsidNucleocapsid ProteinsOryctolagus cuniculusParticulatePlayPopulationPositioning AttributeProcessPropertyProtaminesProtein PrecursorsProteinsRNA-Directed DNA PolymeraseReagentRoleStructureSurfaceSurface ImmunoglobulinsSurface Plasmon ResonanceSystemTimeUniversitiesVaccinesViral ProteinsVirusWorkX-Ray Crystallographyanti-hepatitis Bclinical Diagnosishepatitis B virus P proteinhuman diseaseion mobilitymolecular assembly/self assemblypreventprotein S precursorserological markerstoichiometrytoolvirus core
项目摘要
HBcAg has been expressed in E.coli were it assembles in the bacterial cytoplasm into icosahedral capsids, which contain bound host nucleic acid. Deletion of the polybasic C-terminal 34 residues (protamine domain) also produces assembly competent protein. The capsids from C-terminal truncated protein (Cp149) do not contain nucleic acid and their structure has been previously determined by cryo-electron microscopy and image analysis and by X-ray crystallography. Native HBeAg is also C-terminally truncated at position 149 and in addition contains a 10 residue N-terminal extension derived from partial processing of precursor protein (pre-C). Although detailed knowledge of the function and structure of HBeAg are unknown it has clinical importance as a serological marker. Using surface plasmon resonance (Biacore) to measure antibody antigen interactions, a kinetic-affinity map of a panel of monoclonal antibodies (mAbs) against HBV nucleocapsid proteins was determined. Monoclonal antibodies (murine origin) binding to the assembled (HBcAg) and non-assembled forms of the capsids (HBeAg) were identified and new combinations useful for clinical diagnosis described. Previous structural determinations of nucleocapsid-antibody immune complexes by cryo-electron microscopy helped to more clearly explain the immunological distinction between the assembled HBcAg and unassembled HBeAg antigen. This work has been extended to included human antibodies and the preliminary results indicate binding to distinct regions on the capsid surface (epitopes) which we had previously identified using the model murine antibodies. This work, together our previous description of an immune complex of capsids and an antibody representative of the surface immunoglobulin from naive B-cells, provide one of the most complete structural pictures of the interaction of antibodies with a viral protein system related to an important human disease.
Using a rabbit antibody library, monoclonal antibodies (mAbs) were selected then humanized to produce chimeric mAb fragment antigen binding portions (Fab). Fabs against the HBV capsid proteins were selected for high affinity binding to the capsid subunits. The binding of the antibodies prevent the assembly of the capsids (a central functional and structural component of the HBV virus) and may with development provide useful anti-HBV reagents.
Direct determination of the biophysical properties of the HBV capsid protein is limited due to the size of the multiprotein megadalton complex. In collaboration with Albert Heck (Utrecht University) macromolecular tandem and ion mobility mass spectrometry was used to study the stability and conformational diversity of HBV capsids. Very precise mass measurements were made and the exact molecular stoichiometries of HBV nucleocapsid complexes determined for the first time. This work was extended to include measurements of stability and elasticity of the capsids which resulted in the detection of conformational heterogeneity in the capsid population. Also, the stability of the capsids was addressed by the direct determination of the slow exchange of constituent subunits using isotopically labeled protein. The methods and approaches used have general applicability to the study of large molecular assemblies used in nano- and biotechnology
HBcAg已在大肠杆菌中表达,其在细菌细胞质中组装成二十面体衣壳,其含有结合的宿主核酸。多碱基C-末端34个残基(鱼精蛋白结构域)的缺失也产生有组装能力的蛋白。来自C末端截短蛋白(Cp149)的衣壳不含核酸,其结构先前已通过冷冻电子显微镜和图像分析以及X射线晶体学确定。天然HBeAg也在位置149处被C-末端截短,并且另外含有源自前体蛋白(pre-C)的部分加工的10个残基的N-末端延伸。虽然HBeAg的功能和结构的详细知识是未知的,但它作为血清学标志物具有临床重要性。使用表面等离子体共振(Biacore)测量抗体抗原相互作用,确定一组针对HBV核衣壳蛋白的单克隆抗体(mAb)的动力学亲和力图。单克隆抗体(鼠源)结合组装(HBcAg)和非组装形式的衣壳(HBeAg)进行了鉴定,并描述了新的组合用于临床诊断。先前通过冷冻电子显微镜对核衣壳-抗体免疫复合物的结构测定有助于更清楚地解释组装的HBcAg和未组装的HBeAg抗原之间的免疫学区别。这项工作已经扩展到包括人抗体,并且初步结果表明与衣壳表面上的不同区域(表位)结合,我们先前使用模型鼠抗体鉴定了这些区域。这项工作,连同我们先前对衣壳的免疫复合物和代表来自幼稚B细胞的表面免疫球蛋白的抗体的描述,提供了抗体与重要人类疾病相关的病毒蛋白系统相互作用的最完整的结构图片之一。
使用兔抗体文库,选择单克隆抗体(mAb),然后人源化以产生嵌合mAb片段抗原结合部分(Fab)。选择针对HBV衣壳蛋白的Fab以高亲和力结合衣壳亚基。抗体的结合防止衣壳(HBV病毒的中心功能和结构组分)的组装,并且随着开发可以提供有用的抗HBV试剂。
由于多蛋白兆道尔顿复合物的大小,直接测定HBV衣壳蛋白的生物物理性质是有限的。与Albert Heck(乌得勒支大学)合作,使用大分子串联和离子迁移质谱法研究HBV衣壳的稳定性和构象多样性。进行了非常精确的质量测量,并首次确定了HBV核衣壳复合物的精确分子化学计量。这项工作被扩展到包括测量的稳定性和弹性的衣壳,导致在检测的衣壳人口的构象异质性。此外,通过使用同位素标记的蛋白质直接测定组成亚基的缓慢交换来解决衣壳的稳定性。所使用的方法和途径具有普遍适用性的研究大分子组装体中使用的纳米和生物技术
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL T WINGFIELD其他文献
PAUL T WINGFIELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL T WINGFIELD', 18)}}的其他基金
STRUCTURE/FUNCTION OF HIV/SIV ENVELOPE TRANSMEMBRANE GLYCOPROTEIN GP41
HIV/SIV 包膜跨膜糖蛋白 GP41 的结构/功能
- 批准号:
6289042 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Structure And Assembly Of The Hepatitis B Nucleocapsid
乙型肝炎核衣壳的结构和组装
- 批准号:
6823097 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Structure/function--HIV/SIV EnvelopeTransmembrane Gp41
结构/功能--HIV/SIV包膜跨膜Gp41
- 批准号:
7007430 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Structure/Function of HIV/SIV Envelope Transmembrane Glycoprotein Gp41
HIV/SIV 包膜跨膜糖蛋白 Gp41 的结构/功能
- 批准号:
7964901 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Structure And Assembly Of The Hepatitis B Nucleocapsid Protein
乙型肝炎核衣壳蛋白的结构和组装
- 批准号:
8746496 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Structure/Function of HIV/SIV Envelope Transmembrane Glycoprotein Gp41
HIV/SIV 包膜跨膜糖蛋白 Gp41 的结构/功能
- 批准号:
8344709 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Structure And Assembly Of The Hepatitis B Nucleocapsid P
乙型肝炎核衣壳 P 的结构和组装
- 批准号:
6680169 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Production Of HIV And HIV Related Proteins For Structura
用于 Structura 的 HIV 和 HIV 相关蛋白的生产
- 批准号:
6680165 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Production Of HIV And HIV Related Proteins For Structural Studies
用于结构研究的 HIV 和 HIV 相关蛋白的生产
- 批准号:
8559288 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
Production Of HIV And HIV Related Proteins For Structural Studies
用于结构研究的 HIV 和 HIV 相关蛋白的生产
- 批准号:
10018384 - 财政年份:
- 资助金额:
$ 71.66万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 71.66万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 71.66万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 71.66万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 71.66万 - 项目类别:














{{item.name}}会员




